Routine vs. Aggressive upstream rhythm Control for prevention of Early persistent atrial fibrillation in heart failure study - RACE 3
Contribution To Literature:
The RACE 3 trial showed that upstream risk factor modification was superior at maintaining sinus rhythm.
The goal of the trial was to evaluate upstream risk factor modification compared with conventional therapy among patients with early persistent atrial fibrillation.
Patients with early persistent atrial fibrillation and heart failure were randomized to upstream therapy (n = 119) versus conventional therapy (n = 126).
Upstream therapy consisted of mineralocorticoid receptor antagonist, statin, angiotensin-converting enzyme (ACE) inhibitor and/or angiotensin receptor blocker, and cardiac rehabilitation.
- Early persistent atrial fibrillation and mild to moderate heart failure
- Total number of enrollees: 245
- Duration of follow-up: 1 year
The primary outcome, incidence of sinus rhythm at 1 year, occurred in 75% of the upstream therapy group versus 63% of the conventional therapy group (p = 0.021).
Among patients with early persistent atrial fibrillation, upstream risk factor modification was effective at maintaining sinus rhythm at 1 year. Use of mineralocorticoid receptor antagonists, statins, ACE inhibitor and/or angiotensin receptor blockers, and cardiac rehabilitation can be considered in patients with persistent atrial fibrillation.
Presented by Dr. Michiel Rienstra at the European Society of Cardiology Congress, Barcelona, Spain, August 27, 2017.
Clinical Topics: Arrhythmias and Clinical EP, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Nonstatins, Novel Agents, Statins, Acute Heart Failure
Keywords: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Arrhythmias, Cardiac, Atrial Fibrillation, Cardiac Rehabilitation, ESC Congress, ESC2017, Heart Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mineralocorticoid Receptor Antagonists, Primary Prevention, Risk Factors
< Back to Listings